Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KAT6A | Q92794 | 7/20 | 0.42 |
| ▸ | KAT7 | O95251 | 5/20 | 0.42 |
| ▸ | KAT6B | Q8WYB5 | 4/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | KAT5 | Q92993 | 1/20 | 0.40 |
| ▸ | KAT8 | Q9H7Z6 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31172604 | 0.88 | KAT7 (0.44) | KAT6AKAT7KAT6BHDAC6KAT5 | |
| SCHEMBL31516757 | 0.88 | KAT7 (0.54) | KAT6AKAT7KAT6BHDAC6KAT5 | |
| SCHEMBL31516644 | 0.88 | GLA (0.45) | KAT6AKAT7KAT6BHDAC6MAPT | |
| SCHEMBL31172714 | 0.87 | KAT7 (0.52) | KAT6AKAT7KAT6BKAT5KAT8 | |
| SCHEMBL31691246 | 0.87 | ALPL (0.43) | KAT6AKAT7KAT6BHDAC6KAT5 | |
| SCHEMBL31516806 | 0.86 | KAT7 (0.42) | KAT6AKAT7KAT6BHDAC6KAT5 | |
| SCHEMBL31516668 | 0.85 | ALPL (0.44) | KAT6AKAT7KAT6BKAT5KAT8 | |
| SCHEMBL31516685 | 0.84 | KAT6A (0.48) | KAT6AKAT7KAT6BMAPTKAT5 | |
| SCHEMBL31516708 | 0.84 | KAT7 (0.44) | KAT6AKAT7KAT6BHDAC6KAT5 | |
| SCHEMBL31516772 | 0.84 | KAT7 (0.44) | KAT6AKAT7KAT6BHDAC6KAT5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260015327-A1 | ACYLSULFONAMIDE KAT6A INHIBITORS | OLEMA PHARMACEUTICALS INC (US) | 2026-01-15 | — | — | US | disclosed |
| US-12428379-B2 | Acylsulfonamide KAT6A inhibitors | OLEMA PHARMACEUTICALS, INC. (US) | 2025-09-30 | — | — | US | disclosed |
| US-20250136553-A1 | ACYLSULFONAMIDE KAT6A INHIBITORS | OLEMA PHARMACEUTICALS, INC. | 2025-05-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250136553-A1 | ACYLSULFONAMIDE KAT6A INHIBITORS | KAT6A, KAT2A, KAT6B | KAT6A 1/4885KAT7 5/4885KAT6B 3/4885 |
| US-12428379-B2 | Acylsulfonamide KAT6A inhibitors | KAT6A, KAT2A, KAT6B | KAT6A 1/4885KAT7 5/4885KAT6B 3/4885 |
| US-20260015327-A1 | ACYLSULFONAMIDE KAT6A INHIBITORS | KAT6A, KAT2A, KAT6B | KAT6A 1/4885KAT7 4/4885KAT6B 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.